The first tier focuses on the health status achieved or retained, ie, core outcomes at the endpoint of treatment: HR-QoL (measured using a generic and a disease-specific PROM), the applicable IOQ to evaluate treatment success [Fig. 3, Fig. S1 (5)], and normalization of prolactin levels with restoration of hyperprolactinemia- and hypogonadism-associated symptoms. The gene discussed is PRL; the disease is hypogonadism.